3 Drugs Stocks Dragging The Industry Down

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 15 points (0.1%) at 17,122 as of Wednesday, Aug. 27, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,632 issues advancing vs. 1,319 declining with 192 unchanged.

The Drugs industry currently sits up 0.2% versus the S&P 500, which is unchanged. On the negative front, top decliners within the industry include Bristol-Myers Squibb Company ( BMY), down 1.0%, and Celgene ( CELG), down 0.6%. A company within the industry that increased today was Grifols ( GRFS), up 2.1%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Alexion Pharmaceuticals ( ALXN) is one of the companies pushing the Drugs industry lower today. As of noon trading, Alexion Pharmaceuticals is down $2.22 (-1.3%) to $170.05 on light volume. Thus far, 412,460 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $169.58-$172.72 after having opened the day at $172.33 as compared to the previous trading day's close of $172.27.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $33.7 billion and is part of the health care sector. Shares are up 29.6% year-to-date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Alexion Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Regeneron Pharmaceuticals ( REGN) is down $3.17 (-0.9%) to $350.88 on light volume. Thus far, 250,405 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 838,000 shares. The stock has ranged in price between $348.39-$354.27 after having opened the day at $354.27 as compared to the previous trading day's close of $354.05.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $34.5 billion and is part of the health care sector. Shares are up 28.6% year-to-date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, solid stock price performance and growth in earnings per share. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Regeneron Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Shire ( SHPG) is down $1.70 (-0.7%) to $242.80 on light volume. Thus far, 258,487 shares of Shire exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $242.74-$244.24 after having opened the day at $243.95 as compared to the previous trading day's close of $244.50.

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. Shire has a market cap of $47.9 billion and is part of the health care sector. Shares are up 73.0% year-to-date as of the close of trading on Tuesday. Currently there are 4 analysts that rate Shire a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Shire Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Dow Falls Sharply, Nasdaq Sinks as Wall Street Weighs Trump's New Trade Threats

Dow Falls Sharply, Nasdaq Sinks as Wall Street Weighs Trump's New Trade Threats

Bond Yields to Slide for Rest of Year Amid Trade Turmoil, Morgan Stanley Says

Bond Yields to Slide for Rest of Year Amid Trade Turmoil, Morgan Stanley Says

Video: 2018 Is Actually a Normal Year for Stock Market Volatility

Video: 2018 Is Actually a Normal Year for Stock Market Volatility

3 Fierce Chinese Tech Stocks to Gamble on Right Now

3 Fierce Chinese Tech Stocks to Gamble on Right Now

General Electric Sells Distributed Power Unit to Advent for $3.25 Billion

General Electric Sells Distributed Power Unit to Advent for $3.25 Billion